NADmed is a translational development project from University of Helsinki. The NAD assays are developed at Anu Wartiovaara's lab to enable research into NAD levels in mitochondrial diseases such as mitochondrial myopathy. NADmed project operates under a Research to Business grant from Business Finland. The business landscape for NAD assays is evaluated and commercialisation routes are explored during the project. The business development team at Helsinki Innovation Services is scouting for partnership opportunities to facilitate adoption of NADmed assay technology. Contact us for partnership and investment opportunities.

Commercial Lead

Jari Närhi

Seasoned executive with wealth of experience from medical devices, health services, technology and business consulting.

Business Developer

Sebastian Soidinsalo

Sebastian is a TTO representative of NADmed with a decade of experience in the diagnostic and life science translational research.

Laboratory Manager

Liliya Euro

Biochemist by training, Liliya is the inventor and developer of NADmed assay and oversees laboratory operations and quality.

Commercial Liaison

Jana Buzkova

With a PhD in Mitochondrial Medicine and a strong experience in translational research, Jana is responsible for research collaborations and industry relations.

Group Leader

Anu Wartiovaara

A leading scientist in the field of translational mitochondrial disease research with 25+ years of experience​

Contact Us For

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Vuorikatu 7, 00100 Helsinki, Finland